Pipeline

Advancing a different future for type 1 diabetes and beyond

Scientist in safety glasses and a face mask holding a test tube in a laboratory

Our commitment today is focused: advancing SAB-142 as a potential best-in-class, redosable, disease-modifying therapy for type 1 diabetes (T1D).

As our clinical journey progresses, we believe that the platform behind it can be extended to other complex autoimmune diseases.

SAB-142 programs

TYPE 1 DIABETES

  • SAFEGUARD Study + long-term extension

    Delaying progression of T1D in people within 100 days of diagnosis

    Stage 3

    Registrational Phase 2b
    Current study, through Phase 3.

  • PRISE-hATG Study

    Delaying progression of T1D in people who are 100 days to 2 years of diagnosis

    Stage 3

    Investigator-led
    Current study, through Phase 3.

  • Delaying onset of Stage 3 T1D

    Stage 2

    Potential future study, through Phase 1.

Transplantation

  • Transplant maintenance in islet cell transplantation

    Potential future study, through Phase 1.

Autoimmunity

  • Celiac disease

    Potential future study, through Phase 1.

  • SLE, scleroderma, polymyositis, dermatomyositis

    Potential future study, through Phase 1.
  • Current studies
  • Potential future studies SAB is not currently funding

Find out more about the SAFEGUARD study in newly diagnosed Stage 3 T1D

Learn more about the PRISE-hATG study in recent and extended onset Stage 3 T1D

See how SAB-142 works

PRISE-hATG=Personalized Response and Immunologic Surveillance of Endogenous C-Peptide Preservation in New, Recent, and Extended New Onset T1D Treated with human Anti-Thymocyte Globulin.
SAFEGUARD=SAFety and Efficacy of Human Anti-thymocyte ImmunoGlobUlin SAB-142 ARresting Progression of Type 1 Diabetes.
SLE=systemic lupus erythematosus.